OSLO, Norway, March 29, 2021 /PRNewswire/ -- On 26 March 2021, the Board of Directors of Nordic Nanovector ASA approved the Company's financial statements for 2020. The Company's 2020 Annual Report is attached and available on Nordic Nanovector ASA's website: www.nordicnanovector.com.
For further information, please contact:
IR enquiries
Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin and intends to actively participate in the commercialisation of Betalutin in the US and other major markets.
Further information can be found at www.nordicnanovector.com.
CONTACT:
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa-publishes-2020-annual-report,c3315434
The following files are available for download:
https://mb.cision.com/Main/9819/3315434/1393628.pdf | Release |
